A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., a company based in Edmonton. Aurora announced the formation of a special committee to review the unsolicited offer following the disclosure by Curaleaf Holdings Inc. of its intention to acquire all shares of Aurora. If successful, this acquisition would result in the formation of a combined cannabis entity operating in 17 countries globally.
Curaleaf, headquartered in Stamford, Conn. and listed on the Toronto Stock Exchange, decided to make its proposal public after failed attempts to engage privately with Aurora’s leadership. Despite sending formal letters of intent on June 23 and July 7, Aurora’s board did not participate in negotiations, according to Curaleaf. The proposed deal involves offering Aurora shareholders $4 US per share and an additional $0.75 US in cash for each Aurora share.
Aurora acknowledged receiving the letters from Curaleaf but disputed claims that it declined to discuss the offer. The Canadian company stated that its independent director was in communication with Curaleaf’s CEO until at least July 24, indicating a willingness to continue dialogue. Aurora plans to establish a special committee of independent directors to evaluate the bid and assess its impact on stakeholders.
While Curaleaf’s interest is seen as positive, TD Cowen analysts expressed concerns that the offer undervalues Aurora’s long-term potential. They highlighted Aurora’s market leadership in medical cannabis, diverse product portfolio, strong financial position, and ability to navigate international regulations as factors that could drive significant value creation in the future.
Curaleaf’s CEO believes that merging the two companies would create value by leveraging Curaleaf’s global distribution network with Aurora’s established international medical cannabis business. The companies collectively generated over $1.5 billion US in revenue in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the proposed acquisition.
The proposed deal aims to provide Aurora shareholders with enhanced exposure to U.S. regulatory trends and a broader global presence. Curaleaf views the potential merger as mutually beneficial for both companies and their shareholders.